|
20.07.2010 Phenom Pro Suite - Phenom Pro Suite generates answers not just images
|
|
Phenom-World BV
producer of the Phenom desktop scanning electron
microscope, announces the launch of a new
software product, the Phenom Pro Suite.
The Phenom Pro Suite applications expand the
functionality of the Phenom by automated
collection of images, visualize samples in 3D,
measure surface roughness and automated fiber
analysis.
 |
 |
|
|
|
|
24.06.2010 New strategic partner in the
Nordic |
|
Phenom-World BV
and Struers
A/S announce the start of a new partnership
making Struers the exclusive distributor for the
Phenom Desktop SEM (scanning electron
microscope) in Denmark, Finland, Norway and
Sweden.
|
|
|
|
|
|
21.06.2010
Bio artificial cornea regeneration
research may bring light to the blind
|
|
Aeon Astron Europe BV
(AAE), enters an agreement
with the Department of Ophthalmology of the Leids Universitair Medisch Centrum (LUMC) to
develop an artificial biocornea to restore sight
for corneal blindness.
|
|
|
|
|
|
31.05.2010 Mucosis Receives Financial
Support from the Dutch Government for Its Flugem Program |
|
Dutch vaccine development company
MUCOSIS B.V.
announced today that it has received an
innovation credit line of approximately € 3 million from
Agentschap NL, an agency of the Dutch Ministry of
Economic Affairs. Mucosis will use this loan towards the
clinical development of its lead product FluGEM™, an
influenza vaccine that can be administered by a simple
spray in the nose. The loan will be redeemed only if the
FluGEM™ clinical development program is concluded
successfully.
|
 |
|
|
|
|
27.05.2010
Astellas moves to Leiden
Bio Science Park |
|
The
Japanese pharma concern Astellas has decided to move to the Leiden
Bio Science Park. On behalf of Astellas, Mr Masao Yoshida, President
and CEO, has signed a contract with Leiden University, owner of the
land, and with project developer G&S Vastgoed (Real Estate).
|
 |
|
|
|
|
27.04.2010
Mucosis Appoints Dr. Roberto Grimaldi As Chief
Medical Officer |
|
Dutch vaccine development company
MUCOSIS B.V.
announced
today that Dr. Roberto Grimaldi, MD was appointed Chief
Medical Officer at Mucosis. Dr. Grimaldi is an
accomplished executive and consultant to the vaccine
industry who brings over 25 years of experience. As an
expert on vaccine development he will lead the Mucosis
development programs into clinical trials in the near
future.
|
|
| |
|
All rights reserved